EMA board meeting: new clinical trials database 'nearing completion'

8 June 2018

At the European Medicines Agency’s (EMA) June management board meeting, members discussed progress in preparations for the agency’s relocation to Amsterdam and other matters related to Brexit, including the impact on implementation of the new EU Clinical Trials Regulation (CTR).

Regulations setting up a new system for registering clinical trials, including a new portal and database, entered into effect in 2014. However, implementation has stalled as development of the tools has taken longer than planned, pushing back the new system by several years.

Discussing progress in the ongoing project, the board said that the release of the portal and database is “nearing completion,” and “in an intensive phase of testing.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK